Home » Stocks » ARDX

Ardelyx, Inc. (ARDX)

Stock Price: $6.31 USD 0.27 (4.47%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 569.47M
Revenue (ttm) 8.01M
Net Income (ttm) -85.23M
Shares Out 90.25M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $6.31
Previous Close $6.04
Change ($) 0.27
Change (%) 4.47%
Day's Open 6.00
Day's Range 5.99 - 6.31
Day's Volume 338,286
52-Week Range 4.22 - 8.82

More Stats

Market Cap 569.47M
Enterprise Value 437.42M
Earnings Date (est) Mar 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 90.25M
Float 66.20M
EPS (basic) -1.00
EPS (diluted) -1.01
FCF / Share -0.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.69M
Short Ratio 12.93
Short % of Float 8.60%
Beta 2.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 71.08
PB Ratio 4.15
Revenue 8.01M
Operating Income -81.99M
Net Income -85.23M
Free Cash Flow -75.06M
Net Cash 132.05M
Net Cash / Share 1.46
Gross Margin 58.42%
Operating Margin -1,023.28%
Profit Margin -1,063.70%
FCF Margin -936.79%
ROA -32.23%
ROE -94.44%
ROIC -57.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.00*
(106.02% upside)
Low
11.0
Current: $6.31
High
15.0
Target: 13.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue5.282.6142.00-24.0331.6228.935.41
Revenue Growth102.57%-93.79%---24.02%9.32%434.71%-
Gross Profit4.682.1433.60-24.0331.6228.935.41
Operating Income-91.26-90.95-65.12-113-29.39-1.56-2.87-8.81
Net Income-94.94-91.30-64.34-112-29.62-3.21-6.56-9.79
Shares Outstanding64.4856.2247.4440.1222.8910.251.130.86
Earnings Per Share-1.47-1.62-1.36-2.80-1.29-0.31-5.82-11.32
Operating Cash Flow-76.48-70.27-65.19-92.53-71.8413.401.8121.98
Capital Expenditures-0.33-0.31-2.36-4.87-3.45-1.86-0.28-0.13
Free Cash Flow-76.81-70.59-67.55-97.40-75.2911.541.5321.85
Cash & Equivalents24816813420110710734.6233.08
Total Debt54.7049.21------
Net Cash / Debt19311913420110710734.6233.08
Assets26018315821311711342.9037.88
Liabilities73.1367.5218.5919.988.0552.7350.2339.12
Book Value18711613919310960.68-63.48-57.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ardelyx, Inc.
Country United States
Employees 88
CEO Michael G. Raab

Stock Information

Ticker Symbol ARDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARDX
IPO Date June 19, 2014

Description

Ardelyx, a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.